Abstract #0824

Dynamic Contrast-enhanced MRI in Renal Tumors: Common Subtype Differentiation using Pharmacokinetics

Haiyi Wang¹, Lu Ma¹, Zihua Su², Ning Huang², Xiao Xu³, Zhipeng Sun⁴, Aitao Guo⁵, and Huiyi Ye¹

¹Department of Radiology, Chinese PLA General Hospital, Beijing, People's Republic of China, ²Lift Science, Advanced Application Team, GE Healthcare China, Beijing, People's Republic of China, ³Lift Science, Advanced Application Team, GE Healthcare China, Shanghai, People's Republic of China, ⁴Department of Radiology, No.1 Hospital of Zhangjiakou, Zhangjiakou, People's Republic of China, ⁵Department of Pathology, Chinese PLA General Hospital, Beijing, People's Republic of China

Synopsis

In this prospective study on pharmacokinetic parameters (K^trans & V_e) of renal tumors, we enrolled the patients with five common subtypes of renal tumor - clear cell renal cell carcinoma (ccRCC), papillary renal cell carcinoma (pRCC), chromophobic renal cell carcinoma (cRCC), uroepithelial carcinoma (UEC), and fat poor angiomyolipoma (fpAML) to undergo DCE-MRI pharmacokinetic studies. Our results demonstrated that ccRCC, pRCC, cRCC, UEC and fpAML are pharmacokinetically different (K^trans & V_e). K^trans could distinguish ccRCC from non-ccRCC (pRCC & cRCC) and differentiate fpAML with non-ccRCC with high specificity and sensitivity, which probably can facilitate the precise treatment of renal tumors in the future clinical practice.

This abstract and the presentation materials are available to members only; a login is required.

Join Here